SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Prednisolone / Neomycin / Tetracycline Formulation

Version 3.6 Revision Date: 09.04.2021 SDS Number: 443933-00015 Date of last issue: 25.08.2020
Date of first issue: 07.01.2016

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name: Prednisolone / Neomycin / Tetracycline Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture: Veterinary product

1.3 Details of the supplier of the safety data sheet

Company: MSD
Walton Manor, Walton
MK7 7AJ Milton Keynes - United Kingdom

Telephone: +1-908-740-4000

E-mail address of person responsible for the SDS: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Skin sensitisation, Category 1: H317: May cause an allergic skin reaction.
Reproductive toxicity, Category 1A: H360D: May damage the unborn child.
Effects on or via lactation: H362: May cause harm to breast-fed children.
Short-term (acute) aquatic hazard, Category 1: H400: Very toxic to aquatic life.
Long-term (chronic) aquatic hazard, Category 1: H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms:

Signal word: Danger

Hazard statements:

H317 May cause an allergic skin reaction.
H360D May damage the unborn child.
H362 May cause harm to breast-fed children.
H410 Very toxic to aquatic life with long lasting effects.
Precautionary statements:

Prevention:
P201 Obtain special instructions before use.
P260 Do not breathe dust.
P263 Avoid contact during pregnancy and while nursing.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P391 Collect spillage.

Hazardous components which must be listed on the label:
Neomycin, sulfate (salt)
Tetracycline hydrochloride

2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Neomycin, sulfate (salt)</td>
<td>1405-10-3 215-773-1</td>
<td>Skin Sens. 1B; H317 Repr. 2; H361d STOT RE 2; H373 (Kidney, inner ear) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 1,000 M-Factor (Chronic aquatic toxicity): 10</td>
<td>&gt;= 3 - &lt; 10</td>
</tr>
<tr>
<td></td>
<td>Tetracycline hydrochloride</td>
<td>64-75-5 200-593-8</td>
<td>Repr. 1A; H360D Lact.H362 STOT RE 2; H373 (Gastrointestinal tract, Nervous sys-</td>
<td>&gt;= 1 - &lt; 2.5</td>
</tr>
</tbody>
</table>
**SAFETY DATA SHEET**
according to Regulation (EC) No. 1907/2006

**Prednisolone / Neomycin / Tetracycline Formulation**

Version 3.6  Revision Date: 09.04.2021  SDS Number: 443933-00015  Date of last issue: 25.08.2020  Date of first issue: 07.01.2016

<table>
<thead>
<tr>
<th>Substance</th>
<th>CAS Number</th>
<th>Acute Tox.</th>
<th>Repr.</th>
<th>STOT RE</th>
<th>aquatic Acute</th>
<th>Aquatic Chronic</th>
</tr>
</thead>
<tbody>
<tr>
<td>prednisolone</td>
<td>50-24-8 200-021-7</td>
<td>Acute Tox. 4; H302 Repr. 2; H361d STOT RE 1; H372 (Bone marrow, Adrenal gland, Liver) Aquatic Chronic 2; H411</td>
<td>&gt;= 0.1 - &lt; 0.25</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

**SECTION 4: First aid measures**

**4.1 Description of first aid measures**

**General advice**: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

**Protection of first-aiders**: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

**If inhaled**: If inhaled, remove to fresh air. Get medical attention.

**In case of skin contact**: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

**In case of eye contact**: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

**If swallowed**: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

**4.2 Most important symptoms and effects, both acute and delayed**

**Risks**: May cause an allergic skin reaction.
May damage the unborn child.
May cause harm to breast-fed children.

Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Nitrogen oxides (NOx)
Chlorine compounds
Metal oxides
Sulphur oxides

5.3 Advice for firefighters

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions: Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions:
- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spills cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up:
- Sweep up or vacuum up spillage and collect in suitable container for disposal.
- Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
- Dust deposits should not be allowed to accumulate on surfaces, as they may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures:
- Static electricity may accumulate and ignite suspended dust causing an explosion.
- Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation:
- If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling:
- Avoid contact during pregnancy and while nursing.
- Do not get on skin or clothing.
- Do not breathe dust.
- Do not swallow.
- Avoid contact with eyes.
- Wash skin thoroughly after handling.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Keep container tightly closed.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities
- Requirements for storage areas and containers: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.
- Advice on common storage:
  - Do not store with the following product types:
  - Strong oxidizing agents
  - Organic peroxides
  - Explosives
  - Gases

7.3 Specific end use(s)
- Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paraffin waxes and Hydrocarbon waxes</td>
<td>8002-74-2</td>
<td>TWA (Fumes)</td>
<td>2 mg/m3</td>
<td>GB EH40</td>
</tr>
</tbody>
</table>

Further information: The word 'fume' is often used to include gases and vapours. This is not the case for exposure limits where 'fume' should normally be applied to solid particles generated by chemical reactions or condensed from the gaseous state, usually after volatilisation from melted substances. The generation of fume is often accompanied by a chemical reaction such as oxidation or thermal breakdown.

| | STEL (Fumes) | 6 mg/m3 | GB EH40 |

Further information: The word 'fume' is often used to include gases and vapours. This is not the case for exposure limits where 'fume' should normally be applied to solid particles generated by chemical reactions or condensed from the gaseous state, usually after volatilisation from melted substances. The
8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye protection

: Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

: Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material

: Chemical-resistant gloves

Remarks

: Consider double gloving.

Skin and body protection

: Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection

: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Equipment should conform to BS EN 143

Filter type

: Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance

: powder

Colour

: No data available

Odour

: No data available
9.2 Other information

Particle size : No data available
SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions: May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid: Heat, flames and sparks.
Avoid dust formation.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects
Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Components:

Neomycin, sulfate (salt):
Acute oral toxicity: LD50 (Mouse): 2,880 mg/kg
LD50 (Rat): 2,750 mg/kg

Acute toxicity (other routes of administration):
LD50 (Rat): 633 mg/kg
Application Route: Subcutaneous

LD50 (Mouse): 116 mg/kg
Application Route: Intraperitoneal

LD50 (Mouse): 27.6 mg/kg
Application Route: Intravenous

LD50 (Mouse): 275 mg/kg
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Prednisolone / Neomycin / Tetracycline Formulation

Application Route: Subcutaneous

Tetracycline hydrochloride:
Acute oral toxicity : LD50 (Rat): 6,443 mg/kg
LD50 (Mouse): 2,759 mg/kg
Acute toxicity (other routes of administration) : LD50 (Rat): 128 mg/kg
Application Route: Intravenous
LD50 (Mouse): 157 mg/kg
Application Route: Intravenous

Prednisolone:
Acute oral toxicity : LD50 (Mouse): 1,680 mg/kg
LD50 (Rat): > 3,857 mg/kg
Acute inhalation toxicity : Remarks: No data available
Acute dermal toxicity : Remarks: No data available
Acute toxicity (other routes of administration) : LD50 (Rat): 147 mg/kg
Application Route: Subcutaneous
LD50 (Mouse): 767 mg/kg
Application Route: Intraperitoneal

Skin corrosion/irritation
Not classified based on available information.

Components:
Neomycin, sulfate (salt):
Species : Rabbit
Result : Mild skin irritation

Tetracycline hydrochloride:
Remarks : No data available

Prednisolone:
Remarks : No data available

Serious eye damage/eye irritation
Not classified based on available information.

Components:
Neomycin, sulfate (salt):
Prednisolone / Neomycin / Tetracycline Formulation

Species: Rabbit
Result: No eye irritation

Tetracycline hydrochloride:
Remarks: No data available

prednisolone:
Remarks: No data available

Respiratory or skin sensitisation
Skin sensitisation
May cause an allergic skin reaction.
Respiratory sensitisation
Not classified based on available information.

Components:
Neomycin, sulfate (salt):
Exposure routes: Dermal
Species: Humans
Result: positive

Tetracycline hydrochloride:
Remarks: No data available

prednisolone:
Remarks: No data available

Germ cell mutagenicity
Not classified based on available information.

Components:
Neomycin, sulfate (salt):
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster ovary cells
Result: negative
Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: positive
Test Type: in vitro micronucleus test
Result: negative
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Prednisolone / Neomycin / Tetracycline Formulation

Genotoxicity in vivo
- Test Type: Cytogenetic assay
- Species: Mouse
- Cell type: Bone marrow
- Application Route: Intravenous injection
- Result: negative

Tetracycline hydrochloride:

Genotoxicity in vitro
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
- Test Type: Cytogenetic assay
  - Test system: Chinese hamster ovary cells
  - Result: negative
- Test Type: sister chromatid exchange assay
  - Result: negative
- Test Type: Mouse Lymphoma
  - Result: negative

Prednisolone:

Genotoxicity in vitro
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
- Test Type: Mouse Lymphoma
  - Result: negative
- Test Type: sister chromatid exchange assay
  - Result: negative

Genotoxicity in vivo
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  - Species: Rat
  - Application Route: Oral
  - Result: negative
- Test Type: sister chromatid exchange assay
  - Species: Humans
  - Result: negative

Carcinogenicity
Not classified based on available information.

Components:

Neomycin, sulfate (salt):
- Species: Rat
- Exposure time: 2 Years
- Result: negative
Prednisolone / Neomycin / Tetracycline Formulation

Tetracycline hydrochloride:
Species: Rat
Application Route: Oral
Exposure time: 103 W
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 103 W
Result: negative

Prednisolone:
Species: Rat
Application Route: Oral
Exposure time: 18 Months
Result: negative

Reproductive toxicity
May damage the unborn child.
May cause harm to breast-fed children.

Components:
Neomycin, sulfate (salt):

Effects on fertility
Test Type: Three-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity - Parent: NOAEL: 25 mg/kg body weight
Result: No effects on fertility and early embryonic development were detected.

Effects on foetal development
Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Embryo-foetal toxicity: NOAEL: 275 mg/kg body weight
Result: No adverse effects, No teratogenic effects

Test Type: Development
Species: Rat
Application Route: Subcutaneous
Developmental Toxicity: LOAEL: 6 mg/kg body weight
Result: positive

Reproductive toxicity - Assessment
Some evidence of adverse effects on development, based on animal experiments.

Tetracycline hydrochloride:
Effects on fertility
Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 400 mg/kg body weight
Result: No effects on fertility

Effects on foetal development:
- Test Type: Development
- Result: Embryo-foetal toxicity, Specific developmental abnormalities, Skeletal malformations

Reproductive toxicity - Assessment:
- Studies indicating a hazard to babies during the lactation period, May damage the unborn child.

Prednisolone:

Effects on fertility:
- Test Type: Fertility/early embryonic development
- Species: Rat
- Application Route: Subcutaneous
- Fertility: NOAEL: 1 mg/kg body weight
- Result: No effects on fertility

Effects on foetal development:
- Test Type: Embryo-foetal development
- Species: Mouse
- Application Route: Oral
- Developmental Toxicity: LOAEL: 0.5 mg/kg body weight
- Result: Malformations were observed, Cleft palate

- Test Type: Embryo-foetal development
- Species: Rat
- Application Route: Oral
- Developmental Toxicity: LOAEL: 30 mg/kg body weight
- Result: decreased blood formation

- Test Type: Embryo-foetal development
- Species: Rat
- Application Route: Subcutaneous
- Developmental Toxicity: NOAEL: 25 mg/kg body weight
- Result: No effects on foetal development

Reproductive toxicity - Assessment:
- Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Components:

Neomycin, sulfate (salt):
- Target Organs: Kidney, inner ear
- Assessment: May cause damage to organs through prolonged or repeated exposure.
- Remarks: Based on human experience.
Prednisolone / Neomycin / Tetracycline Formulation

**Tetracycline hydrochloride:**
- **Exposure routes:** Oral
- **Target Organs:** Gastrointestinal tract, Nervous system, Skin, Teeth
- **Assessment:** May cause damage to organs through prolonged or repeated exposure.

**prednisolone:**
- **Target Organs:** Bone marrow, Adrenal gland, Liver
- **Assessment:** Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity**

**Components:**

**Neomycin, sulfate (salt):**
- **Species:** Mouse
- **LOAEL:** 30 mg/kg
- **Application Route:** Subcutaneous
- **Exposure time:** 14 d
- **Target Organs:** Kidney

- **Species:** Guinea pig
  - **NOAEL:** 50 mg/kg
  - **LOAEL:** 100 mg/kg
  - **Application Route:** Intramuscular
  - **Exposure time:** 30 - 60 Weeks
  - **Target Organs:** ear

  - **Species:** Guinea pig
    - **NOAEL:** 10 mg/kg
    - **Application Route:** Oral
    - **Exposure time:** 90 d
    - **Remarks:** No significant adverse effects were reported

  - **Species:** Guinea pig
    - **LOAEL:** 100 mg/kg
    - **Application Route:** Subcutaneous
    - **Exposure time:** 34 d

  - **Species:** Dog
    - **LOAEL:** 24 mg/kg
    - **Application Route:** Intramuscular
    - **Exposure time:** 30 d
    - **Target Organs:** Kidney

  - **Species:** Rat
    - **LOAEL:** 25 mg/kg
    - **Application Route:** oral (feed)
    - **Exposure time:** 84 Weeks
    - **Target Organs:** ear
Prednisolone / Neomycin / Tetracycline Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.6</td>
<td>09.04.2021</td>
<td>443933-00015</td>
<td>25.08.2020</td>
<td>07.01.2016</td>
</tr>
</tbody>
</table>

| Symptoms | hearing loss |
| Remarks  | mortality observed |
| Species  | Dog |
| LOAEL    | 20 mg/kg |
| Application Route | Subcutaneous |
| Exposure time | 90 d |
| Target Organs | Kidney |

**Tetracycline hydrochloride:**

| Species | Rat |
| NOAEL   | 625 mg/kg |
| LOAEL   | 1.250 mg/kg |
| Application Route | oral (feed) |
| Exposure time | 13 W |
| Target Organs | Liver |
| Symptoms | Reduced body weight |

| Species | Mouse |
| NOAEL   | 3,750 mg/kg |
| LOAEL   | 7,500 mg/kg |
| Application Route | oral (feed) |
| Exposure time | 13 W |
| Symptoms | Reduced body weight |

**Prednisolone:**

| Species | Rat |
| LOAEL   | 0.6 mg/kg |
| Application Route | Oral |
| Exposure time | 63 Days |
| Target Organs | Bone marrow |

| Species | Dog |
| LOAEL   | 2.5 mg/kg |
| Application Route | Oral |
| Exposure time | 6 Weeks |
| Target Organs | Adrenal gland |

| Species | Rabbit |
| LOAEL   | 1 mg/kg |
| Application Route | Oral |
| Exposure time | 24 Weeks |
| Target Organs | Liver |

**Aspiration toxicity**

Not classified based on available information.

**Components:**

**Tetracycline hydrochloride:**

Not applicable
Experience with human exposure

**Components:**

**Neomycin, sulfate (salt):**
- **Skin contact:** Symptoms: Sensitisation
  Remarks: May irritate skin.
- **Eye contact:** Remarks: May cause eye irritation.
- **Ingestion:** Symptoms: Nausea, Vomiting, Diarrhoea, tinnitus, hearing loss, Loss of balance
  Remarks: May cause sensitisation of susceptible persons.
  May cause photosensitisation.
  Based on Human Evidence

**Tetracycline hydrochloride:**
- **Ingestion:** Target Organs: Teeth
  Symptoms: Gastrointestinal disturbance, Nausea, Vomiting, Diarrhoea, Liver effects, skin rash, central nervous system effects
  Remarks: May cause sensitisation of susceptible persons.
  May cause photosensitisation.
  Based on Human Evidence

**Prednisolone:**
- **Ingestion:** Symptoms: sodium retention, Headache, Vertigo, fluid retention, subcutaneous bleeding, striae, skin atrophy, menstrual irregularities

### SECTION 12: Ecological information

#### 12.1 Toxicity

**Components:**

**Neomycin, sulfate (salt):**
- **Toxicity to daphnia and other aquatic invertebrates:** EC50 (Daphnia magna (Water flea)): > 72 mg/l
  Exposure time: 48 h
  Method: OECD Test Guideline 202
   
  LC50 (Americamysis): 39 mg/l
  Exposure time: 96 h
  Method: US-EPA OPPTS 850.1035

**Toxicity to algae/aquatic plants:** EC50 (Anabaena flos-aquae (cyanobacterium)): 0.00075 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201

  NOEC (Anabaena flos-aquae (cyanobacterium)): 0.0003 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201

  EC50 (Pseudokirchneriella subcapitata (green algae)): 0.0099 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Prednisolone / Neomycin / Tetracycline Formulation

Version 3.6 Revision Date: 09.04.2021 SDS Number: 443933-00015 Date of last issue: 25.08.2020

Date of first issue: 07.01.2016

M-Factor (Acute aquatic toxicity): 1,000

Toxicity to microorganisms: EC50 (Natural microorganism): 107.6 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

EC10 (Natural microorganism): 2.8 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

M-Factor (Chronic aquatic toxicity): 10

Tetracycline hydrochloride:

Toxicity to algae/aquatic plants:
EC50 (Anabaena flos-aquae (cyanobacterium)): 6.2 mg/l
Exposure time: 72 h

NOEC (Anabaena flos-aquae (cyanobacterium)): 2.5 mg/l
Exposure time: 72 h

EC50 (Pseudokirchneriella subcapitata (green algae)): 3.31 mg/l
Exposure time: 72 h

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.032 mg/l
Exposure time: 72 h

EC50 (Microcystis aeruginosa (blue-green algae)): 0.09 mg/l
Exposure time: 7 d

M-Factor (Acute aquatic toxicity): 10

Toxicity to microorganisms: EC50: 0.08 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

M-Factor (Chronic aquatic toxicity): 1

prednisolone:

Toxicity to daphnia and other: EC50 (Daphnia magna (Water flea)): > 85 mg/l
12.2 Persistence and degradability

**Components:**

Neomycin, sulfate (salt):
Biodegradability : Result: rapidly degradable
Biodegradation: 50 %
Exposure time: 1.2 d
Method: OECD Test Guideline 314

12.3 Bioaccumulative potential

**Components:**

Neomycin, sulfate (salt):
Partition coefficient: n-octanol/water : log Pow: < -2

Tetracycline hydrochloride:
Partition coefficient: n-octanol/water : log Pow: -1.37
pH: 7

Prednisolone:
Partition coefficient: n-octanol/water : log Pow: 1.46

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

**Product:**
Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
12.6 Other adverse effects

**Product:**
Endocrine disrupting potential

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

**Product:**
Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

**Contaminated packaging:**
Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

<table>
<thead>
<tr>
<th>ADN</th>
<th>ADR</th>
<th>RID</th>
<th>IMDG</th>
<th>IATA</th>
</tr>
</thead>
<tbody>
<tr>
<td>UN 3077</td>
<td>UN 3077</td>
<td>UN 3077</td>
<td>UN 3077</td>
<td>UN 3077</td>
</tr>
</tbody>
</table>

14.2 UN proper shipping name

<table>
<thead>
<tr>
<th>ADN</th>
<th>ADR</th>
<th>RID</th>
<th>IMDG</th>
<th>IATA</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Neomycin, sulfate (salt), Tetracycline hydrochloride)</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Neomycin, sulfate (salt), Tetracycline hydrochloride)</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Neomycin, sulfate (salt), Tetracycline hydrochloride)</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Neomycin, sulfate (salt), Tetracycline hydrochloride)</td>
<td>Environmentally hazardous substance, solid, n.o.s. (Neomycin, sulfate (salt), Tetracycline hydrochloride)</td>
</tr>
</tbody>
</table>

14.3 Transport hazard class(es)
14.4 Packing group

**ADN**
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

**ADR**
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

**RID**
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

**IMDG**
Packing group : III
Labels : 9

**IATA (Cargo)**
Packing instruction (cargo aircraft) : 956
Packing instruction (LQ) : Y956
Packing group : III
Labels : Miscellaneous

**IATA (Passenger)**
Packing instruction (passenger aircraft) : 956
Packing instruction (LQ) : Y956
Packing group : III
Labels : Miscellaneous

14.5 Environmental hazards

**ADN**
Environmentally hazardous : yes

**ADR**
Environmentally hazardous : yes

**RID**
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Prednisolone / Neomycin / Tetracycline Formulation

Version 3.6 Revision Date: 09.04.2021 SDS Number: 443933-00015 Date of last issue: 25.08.2020

Date of first issue: 07.01.2016

Environmentally hazardous : yes

IMDG
Marine pollutant : yes

IATA (Passenger)
Environmentally hazardous : yes

IATA (Cargo)
Environmentally hazardous : yes

14.6 Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII): Not applicable

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59): Not applicable

REACH - List of substances subject to authorisation (Annex XIV): Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast): Not applicable

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals: Not applicable


<table>
<thead>
<tr>
<th>Quantity 1</th>
<th>Quantity 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>100 t</td>
<td>200 t</td>
</tr>
</tbody>
</table>

Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Prednisolone / Neomycin / Tetracycline Formulation

Version 3.6
Revision Date: 09.04.2021
SDS Number: 443933-00015
Date of last issue: 25.08.2020
Date of first issue: 07.01.2016

IECSC : not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H302 : Harmful if swallowed.
H317 : May cause an allergic skin reaction.
H360D : May damage the unborn child.
H361d : Suspected of damaging the unborn child.
H362 : May cause harm to breast-fed children.
H372 : Causes damage to organs through prolonged or repeated exposure.
H373 : May cause damage to organs through prolonged or repeated exposure.
H373 : May cause damage to organs through prolonged or repeated exposure if swallowed.
H400 : Very toxic to aquatic life.
H410 : Very toxic to aquatic life with long lasting effects.
H411 : Toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity
Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard
Lact. : Effects on or via lactation
Repr. : Reproductive toxicity
Skin Sens. : Skin sensitisation
STOT RE : Specific target organ toxicity - repeated exposure
GB EH40 : UK. EH40 WEL - Workplace Exposure Limits
GB EH40 / TWA : Long-term exposure limit (8-hour TWA reference period)
GB EH40 / STEL : Short-term exposure limit (15-minute reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - Interna-
**Prednisolone / Neomycin / Tetracycline Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.6</td>
<td>09.04.2021</td>
<td>443933-00015</td>
<td>25.08.2020</td>
<td>07.01.2016</td>
</tr>
</tbody>
</table>

**Further information**

Sources of key data used to compile the Safety Data Sheet:

**Classification of the mixture:**

<table>
<thead>
<tr>
<th>Classification procedure:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin Sens. 1 H317 Calculation method</td>
</tr>
<tr>
<td>Repr. 1A H360D Calculation method</td>
</tr>
<tr>
<td>Lact. H362 Calculation method</td>
</tr>
<tr>
<td>Aquatic Acute 1 H400 Calculation method</td>
</tr>
<tr>
<td>Aquatic Chronic 1 H410 Calculation method</td>
</tr>
</tbody>
</table>

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.